The preventive effect on respiratory tract infections of Oscillococcinum®. A cost-effectiveness analysis
Giorgio L Colombo,1,2 Sergio Di Matteo,2 Chiara Martinotti,2 Martina Oselin,2 Giacomo M Bruno,2 Gianfranco M Beghi3 1Department of Drug Sciences, University of Pavia, Pavia, Italy; 2S.A.V.E. Studi Analisi Valutazioni Economiche S.r.l., Health Economics & Outcomes Research, Milan, Italy; 3Unit of...
Saved in:
Main Authors: | Colombo GL (Author), Di Matteo S (Author), Martinotti C (Author), Oselin M (Author), Bruno GM (Author), Beghi GM (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes
by: Torre E, et al.
Published: (2018) -
Oscillococcinum® for upper respiratory tract infections and exacerbations in COPD: an observational, prospective study (OXITUNIS)
by: Hichem Aouina, et al.
Published: (2021) -
Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study
by: Canonica GW, et al.
Published: (2020) -
Oscillococcinum for influenza treatment
by: Luigi Alberto Marrari, et al.
Published: (2012) -
Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
by: Torre E, et al.
Published: (2020)